Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice

Brunt, 2015, Nonalcoholic fatty liver disease, Nat Rev Dis Prim, 1 Diehl, 2017, Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis, N Engl J Med, 377, 2063, 10.1056/NEJMra1503519 Younossi, 2019, The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis, J Hepatol, 71, 793, 10.1016/j.jhep.2019.06.021 Younossi, 2016, Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes, Hepatology, 64, 73, 10.1002/hep.28431 Loomba, 2021, Mechanisms and disease consequences of nonalcoholic fatty liver disease, Cell, 184, 2537, 10.1016/j.cell.2021.04.015 Angulo, 2015, Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease, Gastroenterology, 149, 389, 10.1053/j.gastro.2015.04.043 Hagström, 2018, Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: a long-term follow-up study, Hepatol Commun, 2, 48, 10.1002/hep4.1124 Romero, 2020, The race to bash NASH: emerging targets and drug development in a complex liver disease, J Med Chem, 10.1021/acs.jmedchem.9b01701 Anstee, 2013, The genetics of NAFLD, Nat Rev Gastroenterol Hepatol, 10, 645, 10.1038/nrgastro.2013.182 Trépo, 2020, Update on NAFLD genetics: from new variants to the clinic, J Hepatol, 72, 1196, 10.1016/j.jhep.2020.02.020 Arroyave-Ospina, 2021, Role of oxidative stress in the pathogenesis of non-alcoholic fatty liver disease: implications for prevention and therapy, Antioxidants (Basel, Switzerland), 10, 1 Madan, 2006, Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD), J Clin Gastroenterol, 40, 930, 10.1097/01.mcg.0000212608.59090.08 Palmieri, 2006, Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome, J Nutr, 136, 3022, 10.1093/jn/136.12.3022 Podszun, 2020, 4-HNE immunohistochemistry and image analysis for detection of lipid peroxidation in human liver samples using vitamin E treatment in NAFLD as a proof of concept, J Histochem Cytochem, 68, 635, 10.1369/0022155420946402 Mohs, 2021, Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis, J Hepatol, 74, 638, 10.1016/j.jhep.2020.09.037 Masarone, 2018, Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease, Oxid Med Cell Longev, 2018, 10.1155/2018/9547613 Satapati, 2015, Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver, J Clin Invest, 125, 4447, 10.1172/JCI82204 Koliaki, 2015, Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis, Cell Metab, 21, 739, 10.1016/j.cmet.2015.04.004 Karkucinska-Wieckowska, 2022, Mitochondria, oxidative stress and nonalcoholic fatty liver disease: a complex relationship, Eur J Clin Invest, 52 Dodson, 2019, Modulating NRF2 in disease: timing is everything, Annu Rev Pharmacol Toxicol, 59, 555, 10.1146/annurev-pharmtox-010818-021856 Tong, 2006, Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model, Mol Cell Biol, 26, 2887, 10.1128/MCB.26.8.2887-2900.2006 Tong, 2007, Different electrostatic potentials define ETGE and DLG motifs as hinge and latch in oxidative stress response, Mol Cell Biol, 27, 7511, 10.1128/MCB.00753-07 Zhang, 2003, Distinct cysteine residues in Keap1 are required for Keap1-dependent ubiquitination of Nrf2 and for stabilization of Nrf2 by chemopreventive agents and oxidative stress, Mol Cell Biol, 23, 8137, 10.1128/MCB.23.22.8137-8151.2003 Zhang, 2004, Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex, Mol Cell Biol, 24, 10941, 10.1128/MCB.24.24.10941-10953.2004 Eggler, 2009, Cul3-mediated Nrf2 ubiquitination and antioxidant response element (ARE) activation are dependent on the partial molar volume at position 151 of Keap1, Biochem J, 422, 171, 10.1042/BJ20090471 Wakabayashi, 2004, Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers, Proc Natl Acad Sci U S A, 101, 2040, 10.1073/pnas.0307301101 Itoh, 1997, An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements, Biochem Biophys Res Commun, 236, 313, 10.1006/bbrc.1997.6943 Marini, 1997, hMAF, a small human transcription factor that heterodimerizes specifically with Nrf1 and Nrf2, J Biol Chem, 272, 16490, 10.1074/jbc.272.26.16490 Hayes, 2014, The Nrf2 regulatory network provides an interface between redox and intermediary metabolism, Trends Biochem Sci, 39, 199, 10.1016/j.tibs.2014.02.002 Cuadrado, 2019, Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases, Nat Rev Drug Discov, 18, 295, 10.1038/s41573-018-0008-x Tang, 2014, Role of Nrf2 in chronic liver disease, World J Gastroenterol, 20, 13079, 10.3748/wjg.v20.i36.13079 Meakin, 2014, Mol Cell Biol, 34, 3305, 10.1128/MCB.00677-14 Chowdhry, 2010, Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis, Free Radic Biol Med, 48, 357, 10.1016/j.freeradbiomed.2009.11.007 Sugimoto, 2010, Deletion of nuclear factor-E2-related factor-2 leads to rapid onset and progression of nutritional steatohepatitis in mice, Am J Physiol - Gastrointest Liver Physiol, 298 Okada, 2012, Nrf2 inhibits hepatic iron accumulation and counteracts oxidative stress-induced liver injury in nutritional steatohepatitis, J Gastroenterol, 47, 924, 10.1007/s00535-012-0552-9 Tanaka, 2008, NF-E2-related factor 2 inhibits lipid accumulation and oxidative stress in mice fed a high-fat diet, J Pharmacol Exp Ther, 325, 655, 10.1124/jpet.107.135822 Sharma, 2018, Experimental nonalcoholic steatohepatitis and liver fibrosis are ameliorated by pharmacologic activation of Nrf2 (NF-E2 p45-related factor 2), Cell Mol Gastroenterol Hepatol, 5, 367, 10.1016/j.jcmgh.2017.11.016 Reisman, 2020, Omaveloxolone and TX63682 are hepatoprotective in the STAM mouse model of nonalcoholic steatohepatitis, J Biochem Mol Toxicol, 2020, 34 Azzimato, 2020, Liver macrophages inhibit the endogenous antioxidant response in obesity-associated insulin resistance, Sci Transl Med, 12, 10.1126/scitranslmed.aaw9709 Bricambert, 2018, The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity, Nat Commun, 9 Yore, 2011, Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR, PLoS One, 6, 10.1371/journal.pone.0022862 de Zeeuw, 2013, Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease, N Engl J Med, 369, 2492, 10.1056/NEJMoa1306033 Chin, 2014, Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl, J Card Fail, 20, 953, 10.1016/j.cardfail.2014.10.001 Li, 2004, Crystal structure of the Kelch domain of human Keap1, J Biol Chem, 279, 54750, 10.1074/jbc.M410073200 Schmoll, 2017, The Keap1–Nrf2 protein–protein interaction: a suitable target for small molecules, Drug Discov Today Tech, 24, 11, 10.1016/j.ddtec.2017.10.001 Davies, 2016, Monoacidic inhibitors of the Kelch-like ECH-associated protein 1: nuclear factor erythroid 2-related factor 2 (KEAP1:NRF2) protein-protein interaction with high cell potency identified by fragment-based discovery, J Med Chem, 59, 3991, 10.1021/acs.jmedchem.6b00228 Kristiansen, 2016, Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy, World J Hepatol, 8, 673, 10.4254/wjh.v8.i16.673 Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 Morel, 2022, Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosis but not NASH progression, PLoS One, 17 Tran, 2019, A comparative assessment study of known small-molecule Keap1-Nrf2 protein-protein interaction inhibitors: chemical synthesis, binding properties, and cellular activity, J Med Chem, 62, 8028, 10.1021/acs.jmedchem.9b00723 Ma, 2020, Design, synthesis and identification of novel, orally bioavailable non-covalent Nrf2 activators, Bioorg Med Chem Lett, 30, 126852, 10.1016/j.bmcl.2019.126852 Mallinson, 2012, Macrocycles in new drug discovery, Future Med Chem, 4, 1409, 10.4155/fmc.12.93 Wen Wong, 2018, Regulation of the NRF2 transcription factor by andrographolide and organic extracts from plant endophytes, PLoS One, 13 Kobayashi, 2016, Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription, Nat Commun, 7, 10.1038/ncomms11624 Santhekadur, 2018, Preclinical models of non-alcoholic fatty liver disease, J Hepatol, 68, 230, 10.1016/j.jhep.2017.10.031 Machado, 2015, Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease, PLoS One, 10 Lickteig, 2007, Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis, J Biochem Mol Toxicol, 21, 216, 10.1002/jbt.20177 Rinella, 2004, The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance, J Hepatol, 40, 47, 10.1016/j.jhep.2003.09.020 Hansen, 2020, Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis, BMC Gastroenterol, 20, 10.1186/s12876-020-01356-2 Henderson, 2006, Galectin-3 regulates myofibroblast activation and hepatic fibrosis, Proc Natl Acad Sci U S A, 103, 5060, 10.1073/pnas.0511167103 Iacobini, 2011, Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver, J Hepatol, 54, 975, 10.1016/j.jhep.2010.09.020 Slocum, 2016, Keap1/Nrf2 pathway activation leads to a repressed hepatic gluconeogenic and lipogenic program in mice on a high-fat diet, Arch Biochem Biophys, 591, 57, 10.1016/j.abb.2015.11.040 Knatko, 2020, Downregulation of Keap1 confers features of a fasted metabolic state, IScience, 2020, 23 Wang, 2021, Myeloid Nrf2 deficiency aggravates non-alcoholic steatohepatitis progression by regulating YAP-mediated NLRP3 inflammasome signaling, IScience, 24, 10.1016/j.isci.2021.103335 Prestigiacomo, 2018, Nrf2 protects stellate cells from Smad-dependent cell activation, PLoS One, 13, 10.1371/journal.pone.0201044 Furuta, 2020, Emerging roles of liver sinusoidal endothelial cells in nonalcoholic steatohepatitis, Biol, 9, 395, 10.3390/biology9110395 Singh, 2019, Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway, Nat Commun, 10, 10.1038/s41467-018-07859-7 Mouries, 2019, Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development, J Hepatol, 71, 1216, 10.1016/j.jhep.2019.08.005 Schmidlin, 2019, Redox regulation by NRF2 in aging and disease, Free Radic Biol Med, 134, 702, 10.1016/j.freeradbiomed.2019.01.016 Kensler, 2010, Nrf2: friend or foe for chemoprevention?, Carcinogenesis, 31, 90, 10.1093/carcin/bgp231 Schulze, 2015, Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets, Nat Genet, 47, 505, 10.1038/ng.3252 Okawa, 2006, Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity, Biochem Biophys Res Commun, 339, 79, 10.1016/j.bbrc.2005.10.185 Komatsu, 2010, The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1, Nat Cell Biol, 12, 213, 10.1038/ncb2021 He, 2020, NRF2 activates growth factor genes and downstream AKT signaling to induce mouse and human hepatomegaly, J Hepatol, 72, 1182, 10.1016/j.jhep.2020.01.023 Köhler, 2014, Activated Nrf2 impairs liver regeneration in mice by activation of genes involved in cell-cycle control and apoptosis, Hepatology, 60, 670, 10.1002/hep.26964 Chan, 2021, Pharmacological activation of Nrf2 enhances functional liver regeneration, Hepatology, 74, 973, 10.1002/hep.31859